S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:VACC

Vaccitech - VACC Stock Forecast, Price & News

$2.23
-0.24 (-9.72%)
(As of 03/28/2023 05:13 PM ET)
Add
Compare
Today's Range
$2.16
$2.31
50-Day Range
$2.16
$3.15
52-Week Range
$2.02
$7.45
Volume
204,269 shs
Average Volume
66,401 shs
Market Capitalization
$83.18 million
P/E Ratio
14.87
Dividend Yield
N/A
Price Target
$12.67

Vaccitech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
468.0% Upside
$12.67 Price Target
Short Interest
Healthy
0.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Vaccitech in the last 14 days
Based on 21 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.52) to ($3.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

170th out of 1,002 stocks

Pharmaceutical Preparations Industry

70th out of 488 stocks


VACC stock logo

About Vaccitech (NASDAQ:VACC) Stock

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Receive VACC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.

VACC Stock News Headlines

Modern Day Options Trading For Beginners!
These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. pixel
Barclays Trims Vaccitech (NASDAQ:VACC) Target Price to $7.00
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
H.C. Wainwright Keeps Their Buy Rating on Renalytix AI (RNLX)
See More Headlines
Receive VACC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.

VACC Company Calendar

Last Earnings
11/12/2021
Today
3/28/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VACC
Fax
N/A
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.67
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+412.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$5.34 million
Pretax Margin
27.77%

Debt

Sales & Book Value

Annual Sales
$44.70 million
Book Value
$7.24 per share

Miscellaneous

Free Float
34,686,000
Market Cap
$92.13 million
Optionable
Not Optionable
Beta
0.21

Key Executives

  • Mr. William J. Enright MBA (Age 59)
    CEO & Director
    Comp: $754.28k
  • Dr. Margaret Marshall M.D. (Age 65)
    Chief Medical Officer
    Comp: $547.97k
  • Ms. Sarah Gilbert
    Co-Founder
  • Mr. Adrian Hill Ph.D.
    Co-Founder & Scientific Advisor
  • Ms. Gemma Brown
    Chief Financial Officer
  • Mr. Chris Ellis (Age 62)
    Chief Operating Officer
  • Dr. Thomas George Evans M.D. (Age 67)
    Chief Scientific Officer
  • Mr. Graham  GriffithsMr. Graham Griffiths (Age 43)
    Chief Bus. Officer
  • Ms. Elizabeth Eagling-Vose M.B.A.
    Head of Clinical Operations
  • Bernie McDonald
    Head of IP













VACC Stock - Frequently Asked Questions

Should I buy or sell Vaccitech stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VACC shares.
View VACC analyst ratings
or view top-rated stocks.

What is Vaccitech's stock price forecast for 2023?

2 brokerages have issued twelve-month price targets for Vaccitech's shares. Their VACC share price forecasts range from $7.00 to $16.00. On average, they predict the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 412.8% from the stock's current price.
View analysts price targets for VACC
or view top-rated stocks among Wall Street analysts.

How have VACC shares performed in 2023?

Vaccitech's stock was trading at $2.35 at the beginning of 2023. Since then, VACC stock has increased by 5.1% and is now trading at $2.47.
View the best growth stocks for 2023 here
.

Are investors shorting Vaccitech?

Vaccitech saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 14,600 shares, a decrease of 16.6% from the February 28th total of 17,500 shares. Based on an average trading volume of 68,200 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are short sold.
View Vaccitech's Short Interest
.

When is Vaccitech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our VACC earnings forecast
.

How were Vaccitech's earnings last quarter?

Vaccitech plc (NASDAQ:VACC) announced its earnings results on Friday, November, 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.25. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $1.65 million. Vaccitech had a net margin of 11.95% and a trailing twelve-month return on equity of 2.13%.

When did Vaccitech IPO?

(VACC) raised $110 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

What is Vaccitech's stock symbol?

Vaccitech trades on the NASDAQ under the ticker symbol "VACC."

Who are Vaccitech's major shareholders?

Vaccitech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baird Financial Group Inc. (0.25%) and Millennium Management LLC (0.11%). Insiders that own company stock include Christopher Ellis, Graham Griffiths, Joseph Scheeren, Karen A Dawes, M&G Investment Management Ltd, Robin Wright and Sciences Innovation Plc Oxford.
View institutional ownership trends
.

How do I buy shares of Vaccitech?

Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccitech's stock price today?

One share of VACC stock can currently be purchased for approximately $2.47.

How much money does Vaccitech make?

Vaccitech (NASDAQ:VACC) has a market capitalization of $92.13 million and generates $44.70 million in revenue each year. The company earns $5.34 million in net income (profit) each year or $0.15 on an earnings per share basis.

How can I contact Vaccitech?

Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The official website for the company is www.vaccitech.co.uk. The company can be reached via phone at 44-0-18-6581-8808 or via email at ir@vaccitech.co.uk..

This page (NASDAQ:VACC) was last updated on 3/28/2023 by MarketBeat.com Staff